文献速递妇科

T-DXd在FISH阴性、HER2 IHC 1+和2+的原发性子宫内膜癌细胞系及异种移植模型中显示显著临床前活性

Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.
PubMed 文献 · Gynecol Oncol · 2026-02-13

本研究评估了 trastuzumab deruxtecan(T-DXd)对FISH阴性、HER2低表达(IHC 1+至2+)的原发性子宫内膜样腺癌细胞系及异种移植小鼠模型的临床前活性。结果显示T-DXd在体外对HER2 IHC 2+和1+细胞系具有显著细胞毒性,在体内显著抑制肿瘤生长并延长总生存,而在IHC 0细胞系中与对照ADC无显著差异。结论支持T-DXd可用于HER2低表达子宫内膜样腺癌。

要点

  • T-DXd在HER2 FISH阴性、IHC 2+和1+的原发性子宫内膜样腺癌细胞系中显示显著体外细胞毒性。
  • 在HER2 IHC 2+和1+异种移植小鼠模型中,T-DXd显著抑制肿瘤生长并延长总生存。
  • HER2 IHC 0细胞系中T-DXd与对照ADC的细胞死亡无显著差异。

核心结论

  • T-DXd对HER2 FISH阴性、IHC低表达的子宫内膜样腺癌在体外和体内均显示出显著临床前活性。

研究设计与样本

  • 研究采用FISH阴性、HER2低表达的原发性子宫内膜样腺癌细胞系,通过免疫组化、流式细胞术(平均荧光强度)和FISH进行表征。
  • 体外评估细胞活力、DNA损伤、抗体依赖细胞毒性和旁观者杀伤效应;体内采用HER2 2+和1+ FISH阴性子宫内膜样腺癌异种移植小鼠模型评估T-DXd活性。

主要发现

  • T-DXd在HER2 FISH阴性、IHC 2+和1+细胞系中表现出显著体外细胞毒性。
  • 在HER2 IHC 0细胞系中,T-DXd与对照ADC之间的细胞死亡无显著差异。
  • 在HER2 IHC 2+和1+异种移植小鼠模型中,T-DXd高度有效抑制肿瘤生长并显著延长总生存。

临床怎么用

  • 这些发现支持T-DXd的应用范围超越HER2高表达,可能为标准化疗和免疫治疗进展后的HER2低表达子宫内膜样腺癌患者提供新的有效治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Antibody-drug conjugates (ADCs) targeting the human epidermal growth factor receptor 2 (HER2) such as trastuzumab deruxtecan (T-DXd) may offer a novel therapeutic option for endometrial cancer patients with HER2-overexpressing tumors. However, the activity of T-DXd in endometrial cancer patients with low HER2 expression (IHC 2+ or 1+, FISH negative) remains unreported. Accordingly, the objectives of this study were to evaluate T-DXd preclinical activity both in-vitro and in-vivo against primary FISH-negative endometrial endometrioid cancer (EEC) cell lines with IHC 1+ to 2+ HER2 expressions. METHODS: Primary FISH-negative EEC cell lines with low HER2 expression were characterized by immunohistochemistry (IHC), flow cytometry (mean fluorescence intensity, MFI) and FISH assays. T-DXd efficacy was investigated in vitro by evaluating cell viability, DNA damage, antibody-dependent cell cytotoxicity and bystander killing. In vivo activity was assessed in HER2 2+ and 1+ FISH-negative EEC xenograft mouse model. RESULTS: T-DXd demonstrated significant in-vitro cytotoxicity in HER2 FISH-negative, IHC 2+ and 1+ cell lines. By contrast, in the HER2 IHC 0 cell line, no significant difference in cell death was observed between T-DXd and Control ADC. In vivo, T-DXd was highly effective in tumor growth suppression and significantly prolonged overall survival in both HER2 IHC 2+ and 1+ xenograft mouse models. CONCLUSIONS: T-DXd showed remarkable preclinical activity against HER2 FISH-negative, IHC-low EEC both in-vitro and in-vivo. These findings support its use beyond HER2-high expression and may represent a novel and effective treatment option for patients with HER2-low EEC who have progressed on standard chemotherapy and immunotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Palmieri L, Bellone S, Demirkiran C, et al. Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts. Gynecol Oncol. 2026. PMID: 41690203. doi:10.1016/j.ygyno.2026.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。